Indications
Comments
Pre-clinical
P1/IIT
P2
P3
aGvHD
For aGvHD patients failing two previous lines of treatment, P1 IND approval in Jul, 2025
4Q25
Lymphodepletion for cell therapies
Potentially best-in-class lymphodepletion agent as adjunct to CAR-T and TIL therapy. Collaboration with Moffitt to advance to IND filing
2Q26
Cutaneous T Cell Lymphoma
FDA Fast Track and Orphan drug designation. P2 IND approval in 4Q2024. Enrollment expected in 4Q2025 in Moffitt Cancer Center
4Q25
Induction therapy in renal transplant
Potentially a replacement for rATG and a new treatment to reduce long-term dependence on immunosuppressants. IND approval
pending in collaboration with researchers from University of Colorado
pending in collaboration with researchers from University of Colorado
4Q26
3Q28
AIDS: clearance of HIV reservoir in T cells
In vitro POC study proved the lysis of HIV infected T cells and prevention of re-infection. In search of development partner
Search for IIT collaboration
Autoimmune Diseases (MS, T1D, RA)
In search of development partner to advance IIT
Search for collaboration to evaluate development plan and initiate IIT
Solid tumor
Approved IND for VG712 + irradiation + anti-checkpoint inhibitors to treat melanoma. Evaluation of treatments in other cancers
Search for IIT collaboration